Background: Advanced colorectal cancer (CRC) is associated with significant morbidity, which, combined with the adverse effects of cancer treatment, can further impair patient quality of life. The primary objective was to evaluate the impact of Ocoxin oral solution (OOS) in combination with oxaliplatin-based chemotherapy on quality of life. Methods: Forty patients participated in an exploratory, prospective, multicentre clinical trial at the “Hermanos Ameijeiras” University Hospital and the National Institute of Oncology in Havana, Cuba. Quality of life was measured using the EORTC QLQ-C30 and EORTC QLQ-C29 questionnaires. Toxicity was assessed using the NCI-CTC-AE classification, version 4.0. Results: Scores remained stable over time for global quality of life and functional scale criteria, while, regarding symptoms, a reduction in pain perception and loss of appetite was observed at three months. The number and severity of adverse events were lower (4.2% grade 3 - 4) than those reported with this type of chemotherapy. No adverse events (AEs) related to OOS were recorded. Biochemical and nutritional parameters remained stable during treatment. Conclusions: This clinical study is the first report on the use of OOS in patients with metastatic colon cancer, maintaining optimal quality of life and reducing the intensity of chemotherapy toxicity.
References
[1]
Siegel, R.L., Wagle, N.S., Cercek, A., Smith, R.A. and Jemal, A. (2023) Colorectal Cancer Statistics, 2023. CA: ACancerJournalforClinicians, 73, 233-254. https://doi.org/10.3322/caac.21772
[2]
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: ACancerJournalforClinicians, 74, 229-263. https://doi.org/10.3322/caac.21834
[3]
Sonbol, M.B., Mountjoy, L.J., Firwana, B., Liu, A.J., Almader-Douglas, D., Mody, K., et al. (2020) The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMAOncology, 6, e194489. https://doi.org/10.1001/jamaoncol.2019.4489
[4]
Lima Pérez, M., Galán Alvarez, Y.H., Soriano García, J.L., Iglesias Ventura, Y. and Medina Pérez, V.M. (2021) Incidencia y mortalidad en Cuba por cáncer del sistema digestivo, 2015-2017. Revista Cubana de Oncología, 19, e142. https://revoncologia.sld.cu/index.php/onc/article/view/142
[5]
Arnold, M., Abnet, C.C., Neale, R.E., Vignat, J., Giovannucci, E.L., McGlynn, K.A., et al. (2020) Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology, 159, 335-349.e15. https://doi.org/10.1053/j.gastro.2020.02.068
[6]
Vogel, A., Hofheinz, R.D., Kubicka, S. and Arnold, D. (2017) Treatment Decisions in Metastatic Colorectal Cancer—Beyond First and Second Line Combination Therapies. CancerTreatmentReviews, 59, 54-60. https://doi.org/10.1016/j.ctrv.2017.04.007
[7]
Braun, D.P., Gupta, D., Grutsch, J.F. and Staren, E.D. (2011) Can Changes in Health Related Quality of Life Scores Predict Survival in Stages III and IV Colorectal Cancer? HealthandQualityofLifeOutcomes, 9, Article No. 62. https://doi.org/10.1186/1477-7525-9-62
[8]
Lombardi, P., Marandino, L., De Luca, E., Zichi, C., Reale, M.L., Pignataro, D., et al. (2020) Quality of Life Assessment and Reporting in Colorectal Cancer: A Systematic Review of Phase III Trials Published between 2012 and 2018. CriticalReviewsinOncology/Hematology, 146, Article ID: 102877. https://doi.org/10.1016/j.critrevonc.2020.102877
[9]
Bonnetain, F., Borg, C., Adams, R.R., Ajani, J.A., Benson, A., Bleiberg, H., et al. (2017) How Health-Related Quality of Life Assessment Should Be Used in Advanced Colorectal Cancer Clinical Trials. AnnalsofOncology, 28, 2077-2085. https://doi.org/10.1093/annonc/mdx191
[10]
Pandiella-Alonso, A., Díaz-Rodríguez, E. and Sanz, E. (2020) Antitumoral Properties of the Nutritional Supplement Ocoxin Oral Solution: A Comprehensive Review. Nutrients, 12, Article 2661. https://doi.org/10.3390/nu12092661
[11]
Pérez-Peña, J., Díaz-Rodríguez, E., Sanz, E. and Pandiella, A. (2019) Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin. Nutrients, 11, Article 1068. https://doi.org/10.3390/nu11051068
[12]
García‐Perdomo, H.A., Gómez‐Ospina, J.C. and Reis, L.O. (2021) Immunonutrition Hope? Oral Nutritional Supplement on Cancer Treatment. InternationalJournalofClinicalPractice, 75, e14625. https://doi.org/10.1111/ijcp.14625
[13]
Cocks, K., King, M.T., Velikova, G., de Castro, G., Martyn St-James, M., Fayers, P.M., et al. (2012) Evidence-Based Guidelines for Interpreting Change Scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. EuropeanJournalofCancer, 48, 1713-1721. https://doi.org/10.1016/j.ejca.2012.02.059
[14]
Meyerhardt, J.A. and Mayer, R.J. (2005) Systemic Therapy for Colorectal Cancer. NewEnglandJournalofMedicine, 352, 476-487. https://doi.org/10.1056/nejmra040958
[15]
Hoff, P.M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., et al. (2001) Comparison of Oral Capecitabine versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients with Metastatic Colorectal Cancer: Results of a Randomized Phase III Study. JournalofClinicalOncology, 19, 2282-2292. https://doi.org/10.1200/jco.2001.19.8.2282
[16]
Grothey, A., Sargent, D., Goldberg, R.M. and Schmoll, H. (2004) Survival of Patients with Advanced Colorectal Cancer Improves with the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment. JournalofClinicalOncology, 22, 1209-1214. https://doi.org/10.1200/jco.2004.11.037
[17]
Leowattana, W., Leowattana, P. and Leowattana, T. (2023) Systemic Treatment for Metastatic Colorectal Cancer. WorldJournalofGastroenterology, 29, 1569-1588. https://doi.org/10.3748/wjg.v29.i10.1569
[18]
Shin, A.E., Giancotti, F.G. and Rustgi, A.K. (2023) Metastatic Colorectal Cancer: Mechanisms and Emerging Therapeutics. TrendsinPharmacologicalSciences, 44, 222-236. https://doi.org/10.1016/j.tips.2023.01.003
[19]
Ciardiello, D. and Petrillo, A. (2024) Editorial: Optimizing the First-Line Treatment for Metastatic Colorectal Cancer. FrontiersinOncology, 14, Article 1366383. https://doi.org/10.3389/fonc.2024.1366383
[20]
Ducreux, M., Bennouna, J., Hebbar, M., Ychou, M., Lledo, G., Conroy, T., et al. (2010) Capecitabine Plus Oxaliplatin (XELOX) versus 5-Fluorouracil/Leucovorin plus Oxaliplatin (FOLFOX‐6) as First‐line Treatment for Metastatic Colorectal Cancer. InternationalJournalofCancer, 128, 682-690. https://doi.org/10.1002/ijc.25369
[21]
Silva, N.M., Santos, M.A.D., Rosado, S.R., Galvão, C.M. and Sonobe, H.M. (2017) Psychological Aspects of Patients with Intestinal Stoma: Integrative Review. RevistaLatino-AmericanadeEnfermagem, 25, e2950. https://doi.org/10.1590/1518-8345.2231.2950
[22]
Li, J., Yuan, Y., Yang, F., Wang, Y., Zhu, X., Wang, Z., et al. (2019) Expert Consensus on Multidisciplinary Therapy of Colorectal Cancer with Lung Metastases (2019 Edition). JournalofHematology&Oncology, 12, Article No. 16. https://doi.org/10.1186/s13045-019-0702-0
[23]
Prasanna, T., Karapetis, C.S., Roder, D., Tie, J., Padbury, R., Price, T., et al. (2018) The Survival Outcome of Patients with Metastatic Colorectal Cancer Based on the Site of Metastases and the Impact of Molecular Markers and Site of Primary Cancer on Metastatic Pattern. ActaOncologica, 57, 1438-1444. https://doi.org/10.1080/0284186x.2018.1487581
[24]
Nordholm-Carstensen, A., Krarup, P., Jorgensen, L.N., Wille-Jørgensen, P.A. and Harling, H. (2014) Occurrence and Survival of Synchronous Pulmonary Metastases in Colorectal Cancer: A Nationwide Cohort Study. EuropeanJournalofCancer, 50, 447-456. https://doi.org/10.1016/j.ejca.2013.10.009
[25]
Adeleke, A., Adebayo, A.S., Agbaje, K., Olajubutu, O. and Adesina, S.K. (2025) Colorectal Cancer: Therapeutic Approaches and Their Complications. Biomedicines, 13, Article 1646. https://doi.org/10.3390/biomedicines13071646
[26]
Ye, J., Hu, Y., Chen, X., Chang, C. and Li, K. (2023) Comparative Effects of Different Nutritional Supplements on Inflammation, Nutritional Status, and Clinical Outcomes in Colorectal Cancer Patients: A Systematic Review and Network Meta-Analysis. Nutrients, 15, Article 2772. https://doi.org/10.3390/nu15122772
[27]
Moore, M.M., Chua, W., Charles, K.A. and Clarke, S.J. (2010) Inflammation and Cancer: Causes and Consequences. ClinicalPharmacology&Therapeutics, 87, 504-508. https://doi.org/10.1038/clpt.2009.254
[28]
Burden, S.T., Hill, J., Shaffer, J.L. and Todd, C. (2010) Nutritional Status of Preoperative Colorectal Cancer Patients. JournalofHumanNutritionandDietetics, 23, 402-407. https://doi.org/10.1111/j.1365-277x.2010.01070.x
[29]
Janakiram, N.B., Mohammed, A., Madka, V., Kumar, G. and Rao, C.V. (2016) Prevention and Treatment of Cancers by Immune Modulating Nutrients. MolecularNutrition&FoodResearch, 60, 1275-1294. https://doi.org/10.1002/mnfr.201500884
[30]
Kim, C. and Kim, B. (2018) Anti-Cancer Natural Products and Their Bioactive Compounds Inducing ER Stress-Mediated Apoptosis: A Review. Nutrients, 10, Article 1021. https://doi.org/10.3390/nu10081021
[31]
Maiuolo, J., Gliozzi, M., Carresi, C., Musolino, V., Oppedisano, F., Scarano, F., et al. (2021) Nutraceuticals and Cancer: Potential for Natural Polyphenols. Nutrients, 13, Article 3834. https://doi.org/10.3390/nu13113834
[32]
Márquez, J., Mena, J., Hernandez-Unzueta, I., Benedicto, A., Sanz, E., Arteta, B., et al. (2015) Ocoxin® Oral Solution Slows down Tumor Growth in an Experimental Model of Colorectal Cancer Metastasis to the Liver in Balb/c Mice. OncologyReports, 35, 1265-1272. https://doi.org/10.3892/or.2015.4486
[33]
Hernandez-Unzueta, I., Benedicto, A., Olaso, E., Sanz, E., Viera, C., Arteta, B., et al. (2017) Ocoxin Oral Solution® as a Complement to Irinotecan Chemotherapy in the Metastatic Progression of Colorectal Cancer to the Liver. OncologyLetters, 13, 4002-4012. https://doi.org/10.3892/ol.2017.6016
[34]
Renfro, L.A., Loupakis, F., Adams, R.A., Seymour, M.T., Heinemann, V., Schmoll, H., et al. (2016) Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients from First-Line Clinical Trials in the ARCAD Database. JournalofClinicalOncology, 34, 144-150. https://doi.org/10.1200/jco.2015.61.6441
[35]
Cong, Z., Wang, D. and Cao, Y. (2018) The Relationship between Body Mass Index Changes during Chemotherapy and Prognosis of Patients with Advanced Colorectal Cancer: A Retrospective Cohort Study. Medicine, 97, e10843. https://doi.org/10.1097/md.0000000000010843
[36]
Innominato, P.F., Giacchetti, S., Moreau, T., Bjarnason, G.A., Smaaland, R., Focan, C., et al. (2013) Fatigue and Weight Loss Predict Survival on Circadian Chemotherapy for Metastatic Colorectal Cancer. Cancer, 119, 2564-2573. https://doi.org/10.1002/cncr.28072
[37]
Prejac, J., Kekez, D., Belev, B., Prejac, M. and Pleština, S. (2021) Frequency of Body Weight Loss Is an Independent Prognostic Factor of First-Line Treatment Outcomes in Metastatic Colorectal Cancer. NutritionandCancer, 74, 520-526. https://doi.org/10.1080/01635581.2021.1900300
[38]
Bhat, A.A., Nisar, S., Singh, M., Ashraf, B., Masoodi, T., Prasad, C.P., et al. (2022) Cytokine-and Chemokine-Induced Inflammatory Colorectal Tumor Microenvironment: Emerging Avenue for Targeted Therapy. CancerCommunications, 42, 689-715. https://doi.org/10.1002/cac2.12295
[39]
Formica, V., Luccchetti, J., Cunningham, D., Smyth, E.C., Ferroni, P., Nardecchia, A., et al. (2014) Systemic Inflammation, as Measured by the Neutrophil/Lymphocyte Ratio, May Have Differential Prognostic Impact before and during Treatment with Fluorouracil, Irinotecan and Bevacizumab in Metastatic Colorectal Cancer Patients. MedicalOncology, 31, Article No. 166. https://doi.org/10.1007/s12032-014-0166-6
[40]
Shen, X., Xiang, M., Tang, J., Xiong, G., Zhang, K., Xia, T., et al. (2024) Evaluation of Peripheral Blood Inflammation Indexes as Prognostic Markers for Colorectal Cancer Metastasis. ScientificReports, 14, Article No. 20489. https://doi.org/10.1038/s41598-024-68150-y
[41]
Hernandez-Unzueta, I., Benedicto, A., Romayor, I., Herrero, A., Sanz, E., Arteta, B., et al. (2019) Ocoxin Oral Solution Exerts an Antitumoral Effect in Pancreatic Cancer and Reduces the Stromal-Mediated Chemoresistance. Pancreas, 48, 555-567. https://doi.org/10.1097/mpa.0000000000001277
[42]
Lima-Pérez, M., Soriano-García, J.L., González-Meisozo, M., Soriano-Lorenzo, J.L., Fleites-Calvo, V., Morales-Morgado, D., et al. (2024) Nutritional Supplement Ocoxin® Combined with Gemcitabine-Based Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma. OpenJournalofGastroenterology, 14, 267-287. https://doi.org/10.4236/ojgas.2024.148030
[43]
Wang, J., Li, J., Wei, S., Xu, J., Jiang, X. and Yang, L. (2021) The Ratio of Platelets to Lymphocytes Predicts the Prognosis of Metastatic Colorectal Cancer: A Review and Meta-Analysis. GastroenterologyResearchandPractice, 2021, Article ID: 9699499. https://doi.org/10.1155/2021/9699499
[44]
Plantureux, L., Mège, D., Crescence, L., Carminita, E., Robert, S., Cointe, S., et al. (2020) The Interaction of Platelets with Colorectal Cancer Cells Inhibits Tumor Growth but Promotes Metastasis. CancerResearch, 80, 291-303. https://doi.org/10.1158/0008-5472.can-19-1181
[45]
Stojanovska, V., Prakash, M., McQuade, R., Fraser, S., Apostolopoulos, V., Sakkal, S., et al. (2019) Oxaliplatin Treatment Alters Systemic Immune Responses. BioMed ResearchInternational, 2019, Article ID: 4650695. https://doi.org/10.1155/2019/4650695
[46]
Benedicto, A., Sanz, E. and Márquez, J. (2021) Ocoxin as a Complement to First Line Treatments in Cancer. InternationalJournalofMedicalSciences, 18, 835-845. https://doi.org/10.7150/ijms.50122
[47]
McGarrah, P., Hubbard, J., Novotny, P.J., Branda, M.E., Sargent, D.S., Morton, R.F., et al. (2023) Baseline Quality of Life Is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer. CancerControl, 30, 1-10. https://doi.org/10.1177/10732748231185047
[48]
Raimondi, A., Di Maio, M., Morano, F., Corallo, S., Lonardi, S., Antoniotti, C., et al. (2020) Health-Related Quality of Life in Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Panitumumab-Based First-Line Treatment Strategy: A Pre-Specified Secondary Analysis of the Valentino Study. European Journal of Cancer, 135, 230-239. https://doi.org/10.1016/j.ejca.2020.04.048
[49]
Miguel, K.L., Ávila, D.R.M., Pérez, L.Á., Rabasa, G.M., Lambert, A.L., Noa, R.E., et al. (2022) The Administration of Ocoxin Increases the Quality of Life of Patients with Advanced Epithelial or Metastatic Ovarian Cancer Undergoing Neoadjuvant Chemotherapy. JournalofCancerTherapy, 13, 561-584. https://doi.org/10.4236/jct.2022.139050
[50]
Fundora Ramos, M., Boulet Maden, L., Oriol Casanova, F., Hernández Cruz, F., Salgado Reyes, C., Hernandez Gato, A., et al. (2020) Oncoxin-Viusid® May Improve Quality of Life and Survival in Patients with Hormonerefractory Prostate Cancer Undergoing Onco-Specific Treatments. MolecularandClinicalOncology, 14, Article No. 5. https://doi.org/10.3892/mco.2020.2167
[51]
Lorente, R.R., Durán, D.H., Viamontes, J.G., Anta, J.L., Reyes, R.O. and Navares, E.S. (2020) Efficacy of Oncoxin-Viusid on the Reduction of Adverse Reactions to Chemotherapy and Radiotherapy in Patients Diagnosed with Cervical Cancer and Endometrial Adenocarcinoma. JournalofCancerTherapy, 11, 276-295. https://doi.org/10.4236/jct.2020.115023
Ruiz de Galarreta, M., Arriazu, E., Pérez de Obanos, M.P., Ansorena, E. and Iraburu, M.J. (2022) Antifibrogenic and Apoptotic Effects of Ocoxin in Cultured Rat Hepatic Stellate Cells. JournalofPhysiologyandBiochemistry, 79, 881-890. https://doi.org/10.1007/s13105-022-00878-5
[54]
Vilar Gomez, E., Rodriguez de Miranda, A., Gra Oramas, B., Arus Soler, E., Llanio Navarro, R., Calzadilla Bertot, L., et al. (2009) Clinical Trial: A Nutritional Supplement Viusid, in Combination with Diet and Exercise, in Patients with Nonalcoholic Fatty Liver Disease. AlimentaryPharmacology&Therapeutics, 30, 999-1009. https://doi.org/10.1111/j.1365-2036.2009.04122.x
[55]
Pérez-Burillo, S., Navajas-Porras, B., López-Maldonado, A., Hinojosa-Nogueira, D., Pastoriza, S. and Rufián-Henares, J.Á. (2021) Green Tea and Its Relation to Human Gut Microbiome. Molecules, 26, Article 3907. https://doi.org/10.3390/molecules26133907
[56]
Zhang, Y., Sheng, Z., Xiao, J., Li, Y., Huang, J., Jia, J., et al. (2023) Advances in the Roles of Glycyrrhizic Acid in Cancer Therapy. FrontiersinPharmacology, 14, Article 1265172. https://doi.org/10.3389/fphar.2023.1265172
[57]
Bak, Y., Lampe, J.W. and Sung, M. (2014) Effects of Dietary Supplementation of Glucosamine Sulfate on Intestinal Inflammation in a Mouse Model of Experimental Colitis. JournalofGastroenterologyandHepatology, 29, 957-963. https://doi.org/10.1111/jgh.12485
[58]
Wan, Y. and Zhang, B. (2022) The Impact of Zinc and Zinc Homeostasis on the Intestinal Mucosal Barrier and Intestinal Diseases. Biomolecules, 12, Article 900. https://doi.org/10.3390/biom12070900
[59]
Hernandez-Unzueta, I., Telleria-Gonzalez, U., Aransay, A.M., Martin Rodriguez, J.E., Sanz, E. and Márquez, J. (2025) Unravelling the Antitumor Mechanism of Ocoxin through Cancer Cell Genomics. FrontiersinPharmacology, 16, Article 1540217. https://doi.org/10.3389/fphar.2025.1540217
[60]
Buck, I., Morceau, F., Grigorakaki, C., Dicato, M. and Diederich, M. (2009) Linking Anemia to Inflammation and Cancer: The Crucial Role of TNFα. BiochemicalPharmacology, 77, 1572-1579. https://doi.org/10.1016/j.bcp.2008.12.018
[61]
Chu, T., Hu, S., Qi, J., Li, X., Zhang, X., Tang, Y., et al. (2022) Bifunctional Effect of the Inflammatory Cytokine Tumor Necrosis Factor Α on Megakaryopoiesis and Platelet Production. JournalofThrombosisandHaemostasis, 20, 2998-3010. https://doi.org/10.1111/jth.15891
[62]
Wang, R.Y., Lin, X.L., Xiang, S.T., Sun, Q.H. and Ding, X.H. (2022) Risk Factors for Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. European Review for Medical and Pharmacological Sciences, 26, 4028-4043. https://doi.org/10.26355/eurrev_202206_28973
[63]
Yang, Y., Zhao, B., Gao, X., Sun, J., Ye, J., Li, J., et al. (2021) Targeting Strategies for Oxaliplatin-Induced Peripheral Neuropathy: Clinical Syndrome, Molecular Basis, and Drug Development. JournalofExperimental&ClinicalCancerResearch, 40, Article No. 331. https://doi.org/10.1186/s13046-021-02141-z
[64]
Mine, K., Kawashiri, T., Mori, K., Mori, Y., Ishida, H., Kudamatsu, H., et al. (2025) Proton Pump Inhibitor Concomitant Use to Prevent Oxaliplatin-Induced Peripheral Neuropathy: Clinical Retrospective Cohort Study. Pharmacotherapy: TheJournalofHumanPharmacologyandDrugTherapy, 45, 435-447. https://doi.org/10.1002/phar.70028
[65]
Moretto, R., Corallo, S., Belfiore, A., Rossini, D., Boccaccino, A., Lonardi, S., et al. (2020) Prognostic Impact of Immune-Microenvironment in Colorectal Liver Metastases Resected after Triplets Plus a Biologic Agent: A Pooled Analysis of Five Prospective Trials. EuropeanJournalofCancer, 135, 78-88. https://doi.org/10.1016/j.ejca.2020.04.045
[66]
Rier, H.N., Jager, A., Sleijfer, S., Maier, A.B. and Levin, M. (2016) The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. TheOncologist, 21, 1396-1409. https://doi.org/10.1634/theoncologist.2016-0066
